Seqirus Presents New Clinical Data that Reinforce the Ability of MF59® Adjuvanted Seasonal and Pandemic Influenza Vaccines to Increase Immune Response - P&T Community

Seqirus Presents New Clinical Data that Reinforce the Ability of MF59® Adjuvanted Seasonal and Pandemic Influenza Vaccines to Increase Immune Response  P&T Community

SUMMIT, N.J., Aug. 30, 2019 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, today presented data at the Options for the Control of Influenza ...



Comments

Popular posts from this blog

Global Influenzavirus B Infection Drug Market 2019 - AbbVie Inc, Adimmune Corp, Altravax Inc, Amarillo Biosciences Inc, Aphios Corp Business Pulze - Business Pulze

Healthcare layoff tracker—Walmart cuts 74 virtual health jobs - Fierce healthcare